Reviews Menomune


No reviews yet.

Menomune Drug Description
Menomune® - A/C/Y/W-135
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
DRUG DESCRIPTION



What are the possible side effects of meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)?

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Menomune »




Menomune®- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A,
C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation
of the group-specific polysaccharide antigens from Neisseria meningitidis,
Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated
with Mueller Hinton agar1 and Watson Scherp2 media. The
purified polysaccharide is extracted from the Neisseria meningitidis cells
and separated from the media by procedures which include centrifugation, detergent
precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
No preservative is added during manufacture.
The 0.78 mL vial of diluent contains sterile, preservative-free, pyrogen-free
distilled water and is used for reconstitution of product supplied in 1 mL vials.
The 6 mL vial of diluent contains sterile, pyrogen-free distilled water to which
thimerosal (mercury derivative) 1:10,000 is added as a preservative. The 6 mL
vial is for reconstitution of product supplied in 10 mL vials. After reconstitution
with diluent as indicated on the label, the 0.5 mL dose is formulated to contain
50 µg of “isolated product” from each of Groups A, C, Y and W-135
in an isotonic sodium chloride solution.
Each dose of vaccine is also formulated to contain 2.5 mg to 5 mg of lactose
added as a stabilizer.3 The vaccine when reconstituted is a clear
colorless liquid.
Potency is evaluated by measuring the molecular size of each polysaccharide
component using a column chromatography method as standardized by the US Food
and Drug Administration (FDA) and the World Health Organization (WHO)4
for Meningococcal Polysaccharide Vaccine.
THIS VACCINE CONFORMS TO THE WORLD HEALTH ORGANIZATION (WHO) REQUIREMENTS.
REFERENCES
1. Mueller H, et al. A protein-free medium for primary isolation
of the gonococcus and meningococcus. Proc Soc Exp Biol Med 48: 330, 1941
2. Watson RG, et al. The specific hapten ofgroup C (group II
a) meningococcus. II. Chemical nature. J Immunol. 81: 337, 1958
3. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide
vaccines by using lactose as a menstruum for lyophilization. Bull WHO 55: 43-48,
1977
4. WHO Technical Report Series, No. 658, 1981Last reviewed on RxList: 9/18/2008




Menomune Drug Description
Menomune® - A/C/Y/W-135
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
DRUG DESCRIPTION



What are the possible side effects of meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)?

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Menomune »




Menomune®- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A,
C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation
of the group-specific polysaccharide antigens from Neisseria meningitidis,
Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated
with Mueller Hinton agar1 and Watson Scherp2 media. The
purified polysaccharide is extracted from the Neisseria meningitidis cells
and separated from the media by procedures which include centrifugation, detergent
precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
No preservative is added during manufacture.
The 0.78 mL vial of diluent contains sterile, preservative-free, pyrogen-free
distilled water and is used for reconstitution of product supplied in 1 mL vials.
The 6 mL vial of diluent contains sterile, pyrogen-free distilled water to which
thimerosal (mercury derivative) 1:10,000 is added as a preservative. The 6 mL
vial is for reconstitution of product supplied in 10 mL vials. After reconstitution
with diluent as indicated on the label, the 0.5 mL dose is formulated to contain
50 µg of “isolated product” from each of Groups A, C, Y and W-135
in an isotonic sodium chloride solution.
Each dose of vaccine is also formulated to contain 2.5 mg to 5 mg of lactose
added as a stabilizer.3 The vaccine when reconstituted is a clear
colorless liquid.
Potency is evaluated by measuring the molecular size of each polysaccharide
component using a column chromatography method as standardized by the US Food
and Drug Administration (FDA) and the World Health Organization (WHO)4
for Meningococcal Polysaccharide Vaccine.
THIS VACCINE CONFORMS TO THE WORLD HEALTH ORGANIZATION (WHO) REQUIREMENTS.
REFERENCES
1. Mueller H, et al. A protein-free medium for primary isolation
of the gonococcus and meningococcus. Proc Soc Exp Biol Med 48: 330, 1941
2. Watson RG, et al. The specific hapten ofgroup C (group II
a) meningococcus. II. Chemical nature. J Immunol. 81: 337, 1958
3. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide
vaccines by using lactose as a menstruum for lyophilization. Bull WHO 55: 43-48,
1977
4. WHO Technical Report Series, No. 658, 1981Last reviewed on RxList: 9/18/2008




Menomune Drug Description
Menomune® - A/C/Y/W-135
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
DRUG DESCRIPTION



What are the possible side effects of meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)?

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Menomune »




Menomune®- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A,
C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation
of the group-specific polysaccharide antigens from Neisseria meningitidis,
Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated
with Mueller Hinton agar1 and Watson Scherp2 media. The
purified polysaccharide is extracted from the Neisseria meningitidis cells
and separated from the media by procedures which include centrifugation, detergent
precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
No preservative is added during manufacture.
The 0.78 mL vial of diluent contains sterile, preservative-free, pyrogen-free
distilled water and is used for reconstitution of product supplied in 1 mL vials.
The 6 mL vial of diluent contains sterile, pyrogen-free distilled water to which
thimerosal (mercury derivative) 1:10,000 is added as a preservative. The 6 mL
vial is for reconstitution of product supplied in 10 mL vials. After reconstitution
with diluent as indicated on the label, the 0.5 mL dose is formulated to contain
50 µg of “isolated product” from each of Groups A, C, Y and W-135
in an isotonic sodium chloride solution.
Each dose of vaccine is also formulated to contain 2.5 mg to 5 mg of lactose
added as a stabilizer.3 The vaccine when reconstituted is a clear
colorless liquid.
Potency is evaluated by measuring the molecular size of each polysaccharide
component using a column chromatography method as standardized by the US Food
and Drug Administration (FDA) and the World Health Organization (WHO)4
for Meningococcal Polysaccharide Vaccine.
THIS VACCINE CONFORMS TO THE WORLD HEALTH ORGANIZATION (WHO) REQUIREMENTS.
REFERENCES
1. Mueller H, et al. A protein-free medium for primary isolation
of the gonococcus and meningococcus. Proc Soc Exp Biol Med 48: 330, 1941
2. Watson RG, et al. The specific hapten ofgroup C (group II
a) meningococcus. II. Chemical nature. J Immunol. 81: 337, 1958
3. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide
vaccines by using lactose as a menstruum for lyophilization. Bull WHO 55: 43-48,
1977
4. WHO Technical Report Series, No. 658, 1981Last reviewed on RxList: 9/18/2008




Menomune Drug Description
Menomune® - A/C/Y/W-135
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
DRUG DESCRIPTION



What are the possible side effects of meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)?

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Menomune »




Menomune®- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A,
C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation
of the group-specific polysaccharide antigens from Neisseria meningitidis,
Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated
with Mueller Hinton agar1 and Watson Scherp2 media. The
purified polysaccharide is extracted from the Neisseria meningitidis cells
and separated from the media by procedures which include centrifugation, detergent
precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
No preservative is added during manufacture.
The 0.78 mL vial of diluent contains sterile, preservative-free, pyrogen-free
distilled water and is used for reconstitution of product supplied in 1 mL vials.
The 6 mL vial of diluent contains sterile, pyrogen-free distilled water to which
thimerosal (mercury derivative) 1:10,000 is added as a preservative. The 6 mL
vial is for reconstitution of product supplied in 10 mL vials. After reconstitution
with diluent as indicated on the label, the 0.5 mL dose is formulated to contain
50 µg of “isolated product” from each of Groups A, C, Y and W-135
in an isotonic sodium chloride solution.
Each dose of vaccine is also formulated to contain 2.5 mg to 5 mg of lactose
added as a stabilizer.3 The vaccine when reconstituted is a clear
colorless liquid.
Potency is evaluated by measuring the molecular size of each polysaccharide
component using a column chromatography method as standardized by the US Food
and Drug Administration (FDA) and the World Health Organization (WHO)4
for Meningococcal Polysaccharide Vaccine.
THIS VACCINE CONFORMS TO THE WORLD HEALTH ORGANIZATION (WHO) REQUIREMENTS.
REFERENCES
1. Mueller H, et al. A protein-free medium for primary isolation
of the gonococcus and meningococcus. Proc Soc Exp Biol Med 48: 330, 1941
2. Watson RG, et al. The specific hapten ofgroup C (group II
a) meningococcus. II. Chemical nature. J Immunol. 81: 337, 1958
3. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide
vaccines by using lactose as a menstruum for lyophilization. Bull WHO 55: 43-48,
1977
4. WHO Technical Report Series, No. 658, 1981Last reviewed on RxList: 9/18/2008




Menomune Drug Description
Menomune® - A/C/Y/W-135
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
DRUG DESCRIPTION



What are the possible side effects of meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)?

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive another meningococcal vaccine in the future, you will need to tell the doctor if the first shot caused any side effects.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side...
Read All Potential Side Effects for Menomune »




Menomune®- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A,
C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation
of the group-specific polysaccharide antigens from Neisseria meningitidis,
Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated
with Mueller Hinton agar1 and Watson Scherp2 media. The
purified polysaccharide is extracted from the Neisseria meningitidis cells
and separated from the media by procedures which include centrifugation, detergent
precipitation, alcohol precipitation, solvent or organic extraction and diafiltration.
No preservative is added during manufacture.
The 0.78 mL vial of diluent contains sterile, preservative-free, pyrogen-free
distilled water and is used for reconstitution of product supplied in 1 mL vials.
The 6 mL vial of diluent contains sterile, pyrogen-free distilled water to which
thimerosal (mercury derivative) 1:10,000 is added as a preservative. The 6 mL
vial is for reconstitution of product supplied in 10 mL vials. After reconstitution
with diluent as indicated on the label, the 0.5 mL dose is formulated to contain
50 µg of “isolated product” from each of Groups A, C, Y and W-135
in an isotonic sodium chloride solution.
Each dose of vaccine is also formulated to contain 2.5 mg to 5 mg of lactose
added as a stabilizer.3 The vaccine when reconstituted is a clear
colorless liquid.
Potency is evaluated by measuring the molecular size of each polysaccharide
component using a column chromatography method as standardized by the US Food
and Drug Administration (FDA) and the World Health Organization (WHO)4
for Meningococcal Polysaccharide Vaccine.
THIS VACCINE CONFORMS TO THE WORLD HEALTH ORGANIZATION (WHO) REQUIREMENTS.
REFERENCES
1. Mueller H, et al. A protein-free medium for primary isolation
of the gonococcus and meningococcus. Proc Soc Exp Biol Med 48: 330, 1941
2. Watson RG, et al. The specific hapten ofgroup C (group II
a) meningococcus. II. Chemical nature. J Immunol. 81: 337, 1958
3. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide
vaccines by using lactose as a menstruum for lyophilization. Bull WHO 55: 43-48,
1977
4. WHO Technical Report Series, No. 658, 1981Last reviewed on RxList: 9/18/2008





Other reviews about Menomune on wordpress

More on Vaccines
  by notdeaddinosaur
Possibly contrary to the impressions of some anti-vaxers, I am not in favor of all vaccines. Not only are all vaccines not created equal, but not all vaccine-preventable […]


Rainy and Gloomy ...
  by Le Zhang
Two days, rainy and without sunshine. Reviewing the Matrix in the dark dorm and rethinking what is real and what is fantasy, the clouds and the rain outside the window […]


Why we don't vaccinate
  by amandaleggett
My husband, wonderful man that he is, took the time to write out exactly why it is that we don't vaccinate and I can't say it any better […]


Guess What's in That Vaccine Cocktail?
  by luminaria
We're headed toward winter and barraged with a plethora of advertising that herds us into line to get flu shots. I thought I should post a warning that […]


Jennifer Garner & Violet
  by babyrazzi
Jennifer was snapped with Violet (who turns 2 in December) at the theater where Jennifer is rehearsing the stage play Cyrano de Bergerac. "She seems to love watching […]


Postsplenectomy Pearls
  by Prem Amalraj
1. Long term antibiotic prophylaxis (Phenoxymethylpenicillin Or erythromycin) 2. Polyvalent Pneumococcal Vaccine ( Pneumovax 23) 0.5ml SC Q 6 years 3. Quadravalent Meningococcal Polysaccharide Vaccine (Menomune) 0.5 ml […]


Vaksin Bebas Thimerosal: Perlu anda tahu..
  by wiratara
Vaksinasi atau adalah pemberian vaksin dari luar tubuh dengan tujuan untuk memberikan kekebalan terhadap penyakit tertentu. Vaksinasi ini akan memberikan kekebalan aktif kepada anak tersebut berupa antibodi terhadap […]


University Of Alabama Implements Mandatory Vaccination Program
  by ancavge
Paul Joseph Watson Prison Planet.com Thursday, July 30, 2009 Another major school institution has implemented a mandatory vaccination policy that bars both new and current students who haven’t received […]


Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease
  by JOC
MMWR  September 25, 2009  V.58  N.37  p.1042-1043 The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons […]


Morning Report 7//30
  by jphmedicalstudent
January 1, 2008 Table of Contents Practice Guidelines ACIP Releases 2008 Child and Adolescent Immunization Schedules JONATHAN L. TEMTE, MD, PhD, University of Wisconsin School of […]



Other reviews about Menomune on web:

Learn about the prescription medication Menomune (Meningococcal Polysaccharide Vaccine), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Menomune (Meningococcal Polysaccharide Vaccine) Drug Information ...


All about Menomune. View complete and up to date Menomune information - part of the Drugs.com trusted medication database. Menomune Facts and Comparisons at Drugs.com


Menomune-A/C/Y/W-135 patient information. Detailed drug information for the consumer, includes dosage, Menomune-A/C/Y/W-135 side effects and more. Menomune-A/C/Y/W-135 consumer information from Drugs.com


Meningococcal Vaccines: Menomune ® and Menactra™ Frequently Asked Questions August 2005 1. What is Menactra ™ (MCV4)? What is Menomune ® (MPSV4)? Meningococcal Vaccines: Menomune ® and Menactra™ Frequently ...


menomune.com Domain name registered by Sanofi Pasteur for corporate and vaccine education. menomune.com


Menomune is used to provide protection against bacterial meningitis. This eMedTV segment gives a detailed overview of this vaccine, with information on the other diseases it can ... Menomune


Menactra contains the same antigens as Menomune, but the antigens are conjugated to diphtheria toxoid. It is hoped that this formulation will overcome the limitations of Menomune. Meningococcal vaccine - Wikipedia, the free encyclopedia


Menomune, MPSV4, Quadrivalent Meningococcal Polysaccharide Vaccine ... http://www.fpnotebook.com/ Menomune Aka: MPSV4, Quadrivalent Meningococcal Polysaccharide Vaccine Menomune


Menomune is a meningococcal vaccine used to prevent bacterial meningitis and other diseases. This eMedTV selection offers more information on Menomune, including details on the ... Menomune Vaccine Information


Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. Neisseria meningitidis - Wikipedia, the free encyclopedia





Featured Reviews

Reviews Aci-Jel

Aci-Jel Drug Description DRUG DESCRIPTION ACI-JEL Vaginal Jelly is a bland, non-irritating, water-dispersible, buffered acid jelly for intravaginal use. ACI-JEL is classified as a Vaginal Therapeutic Jelly. ACI-JEL contains 0.921% glacial...
Read More  |  Review This
Reviews Metformin Hcl

Glumetza Drug Description GLUMETZA® (metformin hydrochloride) Extended Release Tablet, Film Coated DRUG DESCRIPTION What are the possible side effects of metformin (Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)? Get...
Read More  |  Review This
Reviews Sodium Polystyrene

Kayexalate Drug Description Kayexalate® (sodium polystyrene sulfonate, USP) Cation-Exchange Resin DRUG DESCRIPTION What are the possible side effects of sodium polystyrene sulfonate (Kayexalate, Kionex)? Get emergency medical...
Read More  |  Review This
Reviews Dactinomycin

Cosmegen Drug Description COSMEGEN® FOR INJECTION (dactinomycin) for Injection (Actinomycin D) WARNING COSMEGEN® (Dactinomycin for Injection) should be administered only under the supervision of a physician who is experienced...
Read More  |  Review This
Reviews Methyclothiazide

Methyclothiazide Drug Description Methyclothiazide (methyclothiazide) Tablet 5 mg DRUG DESCRIPTION Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. It is an analogue of...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....